Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.56 |
| ▸ | NCF1 | P14598 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | GAK | O14976 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412459 | 0.89 | NCF1 (0.51) | KDM4EMAPTSMN1; SMN2TDP1NTSR1 | |
| SCHEMBL5394879 | 0.89 | NCF1 (0.51) | KDM4EMAPTSMN1; SMN2TDP1NTSR1 | |
| SCHEMBL5405102 | 0.86 | NCF1 (0.56) | KDM4EMAPTSMN1; SMN2NCF1KMT2A | |
| SCHEMBL5402285 | 0.85 | NCF1 (0.58) | KDM4EMAPTSMN1; SMN2NCF1KMT2A | |
| SCHEMBL5409070 | 0.84 | NCF1 (0.57) | KDM4EMAPTSMN1; SMN2TDP1NTSR1 | |
| SCHEMBL5405430 | 0.83 | NCF1 (0.50) | KDM4EMAPTSMN1; SMN2TDP1NTSR1 | |
| SCHEMBL5412027 | 0.83 | NCF1 (0.55) | KDM4EMAPTTDP1L3MBTL1NCF1 | |
| SCHEMBL5397410 | 0.82 | NCF1 (0.72) | KDM4EMAPTSMN1; SMN2RECQLL3MBTL1 | |
| SCHEMBL5401181 | 0.81 | NCF1 (0.74) | KDM4EMAPTSMN1; SMN2RECQLL3MBTL1 | |
| SCHEMBL5036263 | 0.80 | NCF1 (0.61) | KDM4EMAPTNCF1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265125-B2 | Neuropeptide Y antagonists | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20050176698-A1 | Neuropeptide Y antagonists | BREU VOLKER (DE) | 2005-08-11 | — | — | US | disclosed |
| US-6900226-B2 | Neuropeptide Y antagonists | HOFFMAN-LA ROCHE INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1318981-A2 | QUINOLINE AND QUINAZOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-18 | — | — | EP | disclosed |
| US-20020052356-A1 | Neuropeptide Y antagonists | F.HOFFMANN-LA ROCHE AG (CH) | 2002-05-02 | — | — | US | disclosed |
| WO-2002020488-A2 | QUINOLINE AND QUINAZOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176698-A1 | Neuropeptide Y antagonists | NPY5R, NPY4R, NPY2R | KDM4E 1426/4885MAPT 4262/4885SMN1; SMN2 4342/4885 |
| US-20020052356-A1 | Neuropeptide Y antagonists | NPY5R, NPY4R, NPY2R | KDM4E 1426/4885MAPT 4262/4885SMN1; SMN2 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.